Magnus von Knebel Döberitz

Professor at University of Heidelberg, Germany

Magnus von Knebel Döberitz

Magnus von Knebel Döberitz

Professor at University of Heidelberg, Germany

Biography

Dr. Magnus von K. Döberitz, MD, is a Professor at Ruprecht-Karls-Universität Heidelberg.Dr. Döberitz was previously employed as a Director-Supervisory Board & Co-Founder by mtm laboratories AG.

Overview
Career Highlights

mtm laboratories AG

RelSci Relationships

42

Number of Boards

1

Relationships
RelSci Relationships are individuals Magnus von Knebel Döberitz likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at mtm laboratories AG

Relationship likelihood: Strong

Chairman-Ophthalmology Department at University of Heidelberg, Germany

Relationship likelihood: Strong

Section Head of Endocrinology-5th Medical Department, University Medical Center Mannheim at University of Heidelberg, Germany

Relationship likelihood: Strong

Director-Physiology & Pathophysiology at University of Heidelberg, Germany

Relationship likelihood: Strong

General Partner, Life Sciences at Wellington Partners GmbH

Relationship likelihood: Strong

Professor at University of Heidelberg, Germany

Relationship likelihood: Strong

Professor at University of Heidelberg, Germany

Relationship likelihood: Strong

Head, Clinical Development at Isarna Therapeutics GmbH

Relationship likelihood: Strong

Professor at University of Heidelberg, Germany

Relationship likelihood: Strong

Auditor at Telecom Italia SpA

Relationship likelihood: Average

Paths to Magnus von Knebel Döberitz
Potential Connections via
Relationship Science
You
Magnus von Knebel Döberitz
Professor at University of Heidelberg, Germany
Career History
Professor
Current

Ruprecht-Karls-Universität Heidelberg

Co-Founder
1999 - 2013

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer.These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer.

Boards & Committees
Director-Supervisory Board
Prior

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer.These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer.

Investments
Details Hidden

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer.These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer.

Other Affiliations

Magnus von Knebel Döberitz is affiliated with University of Heidelberg, Germany, mtm laboratories AG, mtm laboratories AG

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Magnus von Knebel Döberitz. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Magnus von Knebel Döberitz's profile does not indicate a business or promotional relationship of any kind between RelSci and Magnus von Knebel Döberitz.